MX2023003305A - Composiciones farmaceuticas y metodos de uso del mismo para el tratamiento del cancer. - Google Patents
Composiciones farmaceuticas y metodos de uso del mismo para el tratamiento del cancer.Info
- Publication number
- MX2023003305A MX2023003305A MX2023003305A MX2023003305A MX2023003305A MX 2023003305 A MX2023003305 A MX 2023003305A MX 2023003305 A MX2023003305 A MX 2023003305A MX 2023003305 A MX2023003305 A MX 2023003305A MX 2023003305 A MX2023003305 A MX 2023003305A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- methods
- same
- pharmaceutical compositions
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107010P | 2020-10-29 | 2020-10-29 | |
| PCT/US2021/056809 WO2022093930A1 (en) | 2020-10-29 | 2021-10-27 | Pharmaceutical compositions and methods of using the same for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003305A true MX2023003305A (es) | 2023-04-13 |
Family
ID=81384423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003305A MX2023003305A (es) | 2020-10-29 | 2021-10-27 | Composiciones farmaceuticas y metodos de uso del mismo para el tratamiento del cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12697347B2 (enExample) |
| EP (1) | EP4237094A4 (enExample) |
| JP (2) | JP2023548303A (enExample) |
| KR (1) | KR20230097034A (enExample) |
| CN (2) | CN122182592A (enExample) |
| AU (1) | AU2021369508B2 (enExample) |
| CA (1) | CA3188316A1 (enExample) |
| MX (1) | MX2023003305A (enExample) |
| TW (1) | TW202227096A (enExample) |
| WO (1) | WO2022093930A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US9834576B2 (en) | 2013-10-29 | 2017-12-05 | Otsuka Pharmaceutical Co., Ltd. | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines |
| US10683552B2 (en) | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
| US11224610B2 (en) | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| SG11202108523UA (en) * | 2019-03-25 | 2021-09-29 | Otsuka Pharma Co Ltd | Antitumor composition |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
| WO2021113688A1 (en) | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| EP4090335A1 (en) | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| LT4069254T (lt) | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| JP2024521824A (ja) | 2021-05-27 | 2024-06-04 | ヴァンダービルト ユニヴァーシティ | マクロライド化合物 |
| MX2024003537A (es) | 2021-09-21 | 2024-05-03 | Otsuka Pharma Co Ltd | Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. |
-
2021
- 2021-10-27 JP JP2023526030A patent/JP2023548303A/ja active Pending
- 2021-10-27 AU AU2021369508A patent/AU2021369508B2/en active Active
- 2021-10-27 MX MX2023003305A patent/MX2023003305A/es unknown
- 2021-10-27 WO PCT/US2021/056809 patent/WO2022093930A1/en not_active Ceased
- 2021-10-27 CN CN202610493906.4A patent/CN122182592A/zh active Pending
- 2021-10-27 EP EP21887422.0A patent/EP4237094A4/en active Pending
- 2021-10-27 US US18/250,674 patent/US12697347B2/en active Active
- 2021-10-27 TW TW110139922A patent/TW202227096A/zh unknown
- 2021-10-27 KR KR1020237014585A patent/KR20230097034A/ko active Pending
- 2021-10-27 CN CN202180052939.0A patent/CN116018145A/zh active Pending
- 2021-10-27 CA CA3188316A patent/CA3188316A1/en active Pending
-
2026
- 2026-03-16 JP JP2026042423A patent/JP2026083415A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023548303A (ja) | 2023-11-16 |
| CN116018145A (zh) | 2023-04-25 |
| TW202227096A (zh) | 2022-07-16 |
| KR20230097034A (ko) | 2023-06-30 |
| CA3188316A1 (en) | 2022-05-05 |
| AU2021369508B2 (en) | 2026-07-09 |
| US20230405037A1 (en) | 2023-12-21 |
| US12697347B2 (en) | 2026-08-04 |
| WO2022093930A1 (en) | 2022-05-05 |
| JP2026083415A (ja) | 2026-05-19 |
| AU2021369508A1 (en) | 2023-03-02 |
| CN122182592A (zh) | 2026-06-12 |
| EP4237094A4 (en) | 2024-07-10 |
| EP4237094A1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| MX2023006937A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. | |
| EP4349413A3 (en) | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | |
| MX2010009647A (es) | Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano. | |
| PH12022551502A1 (en) | Substituted straight chain spiro derivatives | |
| NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| RU2014123781A (ru) | Комбинированная терапия с применением антитела к cd20 и человеческого il-15 | |
| MY197462A (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro- 1h-indole compounds for treating cancer | |
| MX2021012901A (es) | Metodo de administracion continua de lenalidomida y otros agentes inmunomoduladores. | |
| RU2016122232A (ru) | Комбинированная терапия на основе антитела к cd20 и ингибитора втк | |
| RU2012131663A (ru) | Композиции и способы лечения рака яичников | |
| MX2020010408A (es) | Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer. | |
| MX2022013406A (es) | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab. | |
| MX2020012611A (es) | Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes. | |
| MX2023015149A (es) | Conjugados de fármacos peptídicos. | |
| MX2023014347A (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| MX2024005484A (es) | Combinaciones antineoplásicas que contienen conjugados de anticuerpo-fármaco anti-ceacam5 y anticuerpos anti-vegfr-2. | |
| AU2018309739A8 (en) | Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia | |
| FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
| CR20220586A (es) | Moléculas de fijación para el tratamiento de cáncer | |
| MX2024011468A (es) | Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia. | |
| MX2024001193A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a sarcoma felino de mcdonough (flt3) y usos de estos. | |
| ES372320A1 (es) | Un procedimiento para la preparacion de alfa, beta-bis (trifluormetil) estilbenos. | |
| WO2023049731A3 (en) | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |